{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:14:07Z","timestamp":1789110847935,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.thromres.2023.01.007","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T03:18:32Z","timestamp":1673579912000},"page":"131-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab"],"prefix":"10.1016","volume":"222","author":[{"given":"Tomoko","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Shinozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Nagatoishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Mitsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Bingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Tsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ei","family":"Kinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.thromres.2023.01.007_bb0005","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.thromres.2023.01.007_bb0010","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1\u20134 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2023.01.007_bb0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.thromres.2023.01.007_bb0020","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2023.01.007_bb0025","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.thromres.2023.01.007_bb0030","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2023.01.007_bb0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia a with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.01.007_bb0040","author":"Shinohara"},{"issue":"6","key":"10.1016\/j.thromres.2023.01.007_bb0045","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab","volume":"16","author":"Nogami","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"09","key":"10.1016\/j.thromres.2023.01.007_bb0050","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia a","volume":"119","author":"M\u00fcller","year":"2019","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2023.01.007_bb0055","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2023.01.007_bb0060","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/jth.14430","article-title":"Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence","volume":"17","author":"Leksa","year":"2019","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2023.01.007_bb0065","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.14359","article-title":"Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2023.01.007_bb0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2023.01.007_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.thromres.2023.01.007_bb0080","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.thromres.2023.01.007_bb0085","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2023.01.007_bb0090","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jth.13134","article-title":"Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive","volume":"13","author":"Waters","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"20","key":"10.1016\/j.thromres.2023.01.007_bb0095","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A","volume":"124","author":"Muto","year":"2014","journal-title":"Blood"},{"issue":"Suppl 6","key":"10.1016\/j.thromres.2023.01.007_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2023.01.007_bb0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MBC.0000000000000921","article-title":"A bispecific antibody demonstrates limited measurability in routine coagulation assays","volume":"31","author":"Hartmann","year":"2020","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"6","key":"10.1016\/j.thromres.2023.01.007_bb0110","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/hae.14177","article-title":"Effects of emicizumab on APTT, FVIII assays and FVIII inhibitor assays using different reagents: results of a UK NEQAS proficiency testing exercise","volume":"26","author":"Lowe","year":"2020","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.thromres.2023.01.007_bb0115","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2023.01.007_bb0120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/hae.13746","article-title":"Evaluation of an automated chromogenic assay for factor VIII clotting activity measurement in patients affected by haemophilia A","volume":"25","author":"Novembrino","year":"2019","journal-title":"Haemophilia"},{"issue":"8","key":"10.1016\/j.thromres.2023.01.007_bb0125","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/jth.14887","article-title":"Non-additive effect on thrombin generation when a plasma-derived factor VIII\/von Willebrand factor (FVIII\/VWF) is combined with emicizumab in vitro","volume":"18","author":"Bravo","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.01.007_bb0130","first-page":"124","article-title":"Development of new APTT reagent using synthetic phospholipids","volume":"3","author":"Okuda","year":"2002","journal-title":"J. Jpn. Soc. Lab. Med."},{"issue":"1","key":"10.1016\/j.thromres.2023.01.007_bb0135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol. Haemost. Thromb."},{"issue":"3","key":"10.1016\/j.thromres.2023.01.007_bb0140","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"9","key":"10.1016\/j.thromres.2023.01.007_bb0145","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","article-title":"A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A","volume":"57","author":"Yoneyama","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.thromres.2023.01.007_bb0150","author":"Masato"},{"issue":"7","key":"10.1016\/j.thromres.2023.01.007_bb0160","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:50:36Z","timestamp":1758736236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384823000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"alternative-id":["S0049384823000063"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.01.007","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}